Chemoembolization — Cost, Top Hospitals & Success Rates | MyMedicPlus

Transarterial chemoembolization (TACE) is a minimally invasive, catheter-based locoregional therapy primarily used for the treatment of hepatocellular carcinoma (HCC) and selected liver metastases. The procedure exploits the fact that liver tumours are predominantly supplied by the hepatic artery, whereas normal liver parenchyma receives its blood supply primarily from the portal vein. By selectively delivering chemotherapy directly into the tumour's arterial blood supply and then embolising the feeding artery to cut off the tumour's blood flow, TACE achieves a dual cytotoxic effect: direct chemotherapy cytotoxicity and ischaemic tumour necrosis from arterial occlusion.

The procedure is performed by an interventional radiologist under fluoroscopic (X-ray) and sometimes cone-beam CT guidance in a catheterisation suite. A microcatheter is navigated via the femoral or radial artery through the hepatic artery to the tumour's feeding vessels, where the treatment mixture is injected under real-time imaging. Two principal techniques exist: conventional TACE (cTACE), in which a mixture of a chemotherapy agent (most commonly doxorubicin, cisplatin, or mitomycin C) and lipiodol (an oily contrast medium that preferentially accumulates in HCC cells) is injected, followed by embolic particles (Gelfoam or PVA) to occlude the artery; and drug-eluting bead TACE (DEB-TACE or DEBDOX), in which microspheres loaded with doxorubicin are injected, releasing drug slowly from the bead matrix while simultaneously causing arterial embolisation.

TACE is recommended by the Barcelona Clinic Liver Cancer (BCLC) staging system as the standard of care for BCLC intermediate-stage HCC (Stage B) — multinodular tumours without vascular invasion or extrahepatic spread, in patients with preserved liver function and good performance status. All treatment decisions for HCC should be made by a multidisciplinary tumour board including hepatology, interventional radiology, oncology, surgery, and pathology.

Hepatocellular carcinoma (HCC) at intermediate BCLC stage B is the primary and best-validated indication for TACE. This includes patients with multinodular tumours not amenable to curative treatment (resection, ablation, or transplantation), preserved liver function (Child-Pugh A or B), absence of main portal vein invasion, and absence of extrahepatic disease. TACE is also used as a bridge to liver transplantation — controlling HCC within Milan criteria while patients wait for a donor organ, reducing drop-off from the transplant waiting list due to tumour progression.

Downstaging of HCC — reducing tumour burden to bring patients within Milan criteria for transplantation who initially exceeded them — is an increasingly used application of TACE and other locoregional therapies. TACE may also be used for colorectal cancer liver metastases (DEBIRI, using irinotecan-loaded beads) in selected patients who have failed systemic chemotherapy, with moderate evidence of progression-free survival benefit. Selected non-colorectal liver metastases (neuroendocrine tumour liver metastases, uveal melanoma metastases) may also benefit from TACE or related embolisation techniques (bland embolisation or radioembolisation). HCC with limited portal vein thrombosis and Child-Pugh A function remains a contested indication; conventional TACE is generally avoided but modified or superselective TACE may be considered at specialist centres.

The BCLC classification guides patient selection for TACE. Ideal candidates have BCLC Stage B disease — multiple HCC nodules confined to the liver without vascular invasion or extrahepatic spread — Child-Pugh A or B liver function (indicating sufficient hepatic reserve to tolerate the ischaemic injury of embolisation), an ECOG performance status of 0–2, and absence of renal impairment that would preclude contrast use. Serum bilirubin below 2 mg/dL, albumin above 3 g/dL, and prothrombin time INR below 1.7 are typical prerequisites. Baseline multiphase CT or MRI of the liver is required to characterise tumour extent, vascular anatomy, and portal vein patency.

Contraindications include severe liver failure (Child-Pugh C), main portal vein thrombosis (risk of hepatic failure from combined arterial and portal venous occlusion), biliary obstruction without adequate bile duct decompression, severe renal impairment (contrast nephropathy risk), large or complete arteriovenous fistula, uncorrectable coagulopathy, and active infection. Prior extensive liver surgery or porto-systemic shunts alter hepatic arterial anatomy and require careful pre-procedure angiographic assessment. All TACE candidates should be reviewed by an experienced multidisciplinary hepatocellular carcinoma team before a treatment decision is made.

Conventional TACE (cTACE) uses lipiodol — an iodised poppy seed oil that is selectively taken up by HCC cells due to the absence of Kupffer cells and lymphatics — as a drug carrier for chemotherapy (doxorubicin 50 mg, cisplatin 100 mg, or mitomycin C 10 mg). The lipiodol-chemotherapy emulsion is injected into the tumour-feeding arteries, followed by embolic particles (Gelfoam pledgets, PVA particles 100–300 microns) to occlude arterial flow. The lipiodol retention on CT scan one to four weeks post-procedure confirms tumour targeting and extent of treatment. cTACE remains the most widely used technique globally and has the most extensive evidence base.

Drug-eluting bead TACE (DEB-TACE) uses calibrated microspheres (DC Beads, HepaSphere) pre-loaded with doxorubicin that are delivered into the tumour artery, where they both embolise the vessel and release doxorubicin slowly over days to weeks. The theoretical advantage is more sustained intratumoral drug concentration with lower systemic doxorubicin exposure and fewer systemic side effects. The PRECISION V trial showed comparable tumour response rates to cTACE with significantly reduced hepatotoxicity and systemic side effects, supporting DEB-TACE particularly in patients with impaired liver function. Superselective TACE — using a microcatheter to cannulate fourth or fifth-order hepatic artery branches directly feeding the tumour — maximises intratumoral drug delivery while minimising non-tumoral parenchymal embolisation, and is the preferred technique at experienced centres.

Two landmark randomised controlled trials (Llovet 2002, Lo 2002) established TACE as the first locoregional treatment to demonstrate a survival benefit over best supportive care in intermediate HCC, with a median overall survival of 16–26 months versus 8–12 months for untreated patients. For patients with good liver function and limited tumour burden within the intermediate stage, survival extends significantly beyond two years. Tumour response — defined as modified RECIST (mRECIST) complete response (disappearance of arterial enhancement) or partial response — is achieved in 50–70% of patients after one to two TACE sessions.

As a bridge to liver transplantation, TACE is highly effective — reducing dropout rates from HCC progression on the waiting list by 50–70% in studies from major transplant centres. In the downstaging context, approximately 25–40% of patients can be brought within Milan criteria after repeated TACE, enabling subsequent curative transplantation that would not otherwise have been possible. Quality of life is generally maintained after TACE with mild to moderate post-embolisation syndrome; most patients tolerate multiple sessions and can continue TACE as repeat locoregional therapy until liver function or disease progression limits further treatment.

Post-embolisation syndrome — fever, abdominal pain, nausea, and elevated liver enzymes occurring in the 48–72 hours after TACE — is the most common expected adverse effect, occurring in 60–80% of patients. This is a normal inflammatory response to tumour necrosis and is managed with analgesia, antipyretics, antiemetics, and intravenous hydration. It typically resolves within three to five days. Liver function deterioration — elevation of bilirubin, transaminases, and INR — occurs transiently after TACE and usually resolves within one to two weeks. Clinically significant liver failure occurs in 3–5% of well-selected patients and is more likely in Child-Pugh B patients with limited hepatic reserve.

Non-target embolisation — inadvertent occlusion of arteries supplying normal gallbladder, stomach, or bowel — is a technical complication that can cause cholecystitis, gastric or duodenal ulceration, or bowel ischaemia. Careful pre-procedure angiographic mapping and superselective catheterisation minimise this risk. Hepatic artery injury or thrombosis from repeated catheterisations can preclude future TACE sessions. Tumour rupture — spontaneous rupture of HCC after embolisation causing haemoperitoneum — is a rare but life-threatening emergency (approximately 0.5–1%). Contrast-induced nephropathy requires appropriate hydration and pre-procedure creatinine assessment; patients with borderline renal function may benefit from CO2 angiography or minimised contrast volumes.

After TACE, patients are observed in hospital for 24–48 hours for post-embolisation syndrome monitoring, pain and nausea management, and fluid administration. Liver function tests, full blood count, and creatinine are checked on day one post-procedure and at the outpatient follow-up visit at four to six weeks. Response assessment by multiphasic CT or MRI with mRECIST criteria is performed at four to six weeks after each TACE session to determine tumour response and guide the decision for further treatment.

Repeat TACE sessions are performed on an 'on-demand' basis — guided by response assessment — typically every two to three months until the entire tumour burden has been treated with complete response, the tumour becomes unresponsive (less than 25% reduction in viable tumour), liver function declines below Child-Pugh B7, or technical limitations preclude further catheterisation. After complete locoregional response, AFP level and liver function are monitored three-monthly; long-term hepatic MRI surveillance is performed three to six monthly. HCC can recur at new sites despite successful treatment of index tumours, reflecting the field defect of underlying cirrhosis — continuous surveillance is essential indefinitely.

Transarterial chemoembolization in the United States costs USD 15,000–35,000 per session, reflecting the interventional radiology facility, catheter and bead costs, intraprocedural imaging, and hospitalisation. A patient receiving three to four TACE sessions may incur total treatment costs of USD 50,000–120,000 before considering systemic therapies or transplantation. In the UK, NHS patients receive TACE for HCC at specialist hepatobiliary centres at no direct charge, but NHS access may be limited for patients without established referral networks; private care costs GBP 8,000–20,000 per session.

In India, TACE at leading hepatobiliary centres — Medanta Medicity (Gurugram), Apollo Hospitals, Tata Memorial Hospital (Mumbai), and Narayana Health — costs USD 2,500–6,000 per session, representing savings of 75–85% versus US prices. Thailand (Bangkok Hospital, Bumrungrad) charges USD 5,000–12,000 per session; Turkey (Acibadem, Memorial Hospital) USD 4,000–9,000; Singapore (National Cancer Centre, Mount Elizabeth) USD 8,000–15,000. For HCC patients from South Asia, Southeast Asia, the Middle East, and Africa — regions where HCC incidence is high due to hepatitis B prevalence — access to affordable TACE at JCI-accredited Indian or Thai centres is a meaningful option, provided the patient meets eligibility criteria and a multidisciplinary tumour board review is conducted.

For patients with early-stage HCC (BCLC 0-A), curative options — surgical resection, radiofrequency ablation (RFA), microwave ablation (MWA), or liver transplantation — provide superior outcomes to TACE and should be pursued when feasible. Selective internal radiotherapy (SIRT, also known as radioembolisation with Y-90 microspheres) delivers beta-radiation-loaded microspheres to HCC via the hepatic artery, achieving locoregional control comparable to TACE in retrospective series and potentially superior outcomes in specific subgroups (larger single tumours, portal vein thrombosis) — though head-to-head RCTs have not consistently demonstrated superiority. SIRT is available at a more limited number of centres than conventional TACE.

For advanced HCC with portal vein invasion or extrahepatic spread (BCLC Stage C), systemic therapies — first-line atezolizumab plus bevacizumab (IMBRAVE150 trial), or sorafenib, lenvatinib — are the standard of care; TACE is not recommended as primary treatment in this setting. Stereotactic body radiotherapy (SBRT) provides effective locoregional control for HCC lesions not amenable to ablation, with emerging data supporting its use for portal vein thrombosis. The choice between locoregional and systemic strategies requires individual multidisciplinary assessment considering tumour stage, liver function, performance status, and available expertise.